Skip to content

US · ORKA · BIOTECHNOLOGY

Oruka Therapeutics, Inc. (ORKA) intrinsic value and stock valuation

$95.81as of 2026-11-21 · Mkt cap 5.96B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Oruka Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ORKA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ORKA’s statements →

Oruka Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Menlo Park, CA 94025 orukatx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-105.43M
20112025
Free cash flow
-$-88.42M
20102025
Total equity
$471.9M+58.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-122.05M-$-88.12M-$-7.3M-$-9.84M-$-19.34M
Net income-$-105.43M-$-83.72M-$-5.34M-$-9.93M-$-19.32M
EPSd-$-2.31M-$-4.99M-$-370.32K-$-689.1K-$-1.39M
Operating cash flow-$-88.21M-$-57.84M—-$-10.91M-$-18.76M
Capital expenditure-$-210K-$-190K—-$0.00-$-40K
Free cash flow-$-88.42M-$-58.03M—-$-10.91M-$-18.8M
Total assets$488.6M$396M$37.9M$43.1M$54.9M
Total debt$1.93M$970K$280K$380K$480K
Net debt-$-45M-$-60.61M-$-37.15M-$-42.06M-$-52.88M
Total equity$471.9M$382.2M$37M$41.7M$51M
Cash and short-term investments$337M$375.7M$37.4M$42.5M$53.4M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$80K$30K$110K$110K$90K
Gross profit-$-80K-$-30K-$-110K-$-110K-$-90K
Research and development expenses$100.6M$75.1M$1.01M$4.46M$13.8M
Selling, general and administrative expenses$21.3M$13M$6.17M$5.26M$5.41M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$122M$88.1M$7.18M$9.73M$19.2M
Cost and expenses$122.1M$88.1M$7.3M$9.84M$19.3M
Interest income$16.6M$5.86M$1.96M$680K$0.00
Interest expense$0.00$1.47M$0.00$0.00$0.00
Depreciation and amortization$80K$30K$110K$110K$90K
Ebitda-$-105.35M-$-82.23M-$-5.23M-$-9.81M-$-19.23M
Operating income-$-122.05M-$-88.12M-$-7.3M-$-9.84M-$-19.34M
Total other income/expenses, net$16.6M$4.4M$1.96M-$-90K$10K
Income before tax-$-105.43M-$-83.72M-$-5.34M-$-9.93M-$-19.32M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-105.43M-$-83.72M-$-5.34M-$-9.93M-$-19.32M
Weighted average shares outstanding$45.6M$16.8M$14.4M$14.4M$13.9M
Weighted average diluted shares outstanding$45.6M$16.8M$14.4M$14.4M$13.9M
Balance sheet
20252024202320222021
Cash and short-term investments$337M$375.7M$37.4M$42.5M$53.4M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$343.9M$376.9M$37.6M$42.7M$54.4M
Property, plant and equipment, net$2.12M$1.04M$260K$370K$480K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$142.5M$18.1M$0.00$0.00$0.00
Total non-current assets$144.8M$19.2M$270K$390K$500K
Total assets$488.6M$396M$37.9M$43.1M$54.9M
Accounts payable$4.16M$3.46M$0.00$330K$1.12M
Short-term debt$620K$210K$80K$100K$100K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$15.4M$13M$640K$1.13M$3.5M
Long-term debt$1.31M$760K$200K$280K$380K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.31M$760K$200K$280K$380K
Capital lease obligations$1.31M$760K$200K$280K$380K
Total liabilities$16.7M$13.8M$840K$1.41M$3.88M
Common stock$50K$40K$10K$10K$10K
Retained earnings-$-189.16M-$-83.72M-$-188.74M-$-183.4M-$-173.48M
Accumulated other comprehensive income (loss)$550K-$-40K$0.00$0.00$0.00
Total equity$471.9M$382.2M$37M$41.7M$51M
Total investments$432.7M$332.1M$0.00$0.00$0.00
Total debt$1.93M$970K$280K$380K$480K
Net debt-$-45M-$-60.61M-$-37.15M-$-42.06M-$-52.88M
Cash flow statement
20252024202220212020
Net income-$-105.43M-$-83.72M-$-9.93M-$-19.32M-$-9.74M
Depreciation and amortization$80K$30K$110K$90K$90K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-2.56M$11.6M-$-1.66M-$-30K$1.88M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$690K$3.46M-$-780K-$-410K$1.1M
Net cash provided by operating activities-$-88.21M-$-57.84M-$-10.91M-$-18.76M-$-7.72M
Investments in property, plant and equipment-$-210K-$-190K-$0.00-$-40K-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-96.75M-$-330.13M-$0.00-$-40K-$-20K
Common stock issued$170.3M$449.5M$0.00$23.1M$48.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$170.3M$449.5M$0.00$23.1M$48.5M
Net change in cash-$-14.64M$24.1M-$-10.91M$4.29M$40.7M
Cash at end of period$46.9M$61.6M$42.5M$53.4M$49.1M
Operating cash flow-$-88.21M-$-57.84M-$-10.91M-$-18.76M-$-7.72M
Capital expenditure-$-210K-$-190K-$0.00-$-40K-$-20K
Free cash flow-$-88.42M-$-58.03M-$-10.91M-$-18.8M-$-7.74M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Oruka Therapeutics, Inc.

        Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

        CEO
        Lawrence Otto Klein
        Employees
        68
        Beta
        -0.39

        Explore

        Frequently asked questions

        What is the intrinsic value of Oruka Therapeutics, Inc. (ORKA)?

        InvestorsCraft does not currently publish an intrinsic value for ORKA. How the IC value is calculated.

        Is ORKA undervalued?

        InvestorsCraft does not publish an undervaluation signal for ORKA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.